TLR3 and TLR4 SNP Variants in the Liver Disease Resulting from Hepatitis B Virus and Hepatitis C Virus Infection
Overview
Affiliations
Background: Chronic infection with hepatitis B (HBV) and C virus (HCV) is linked with a pro-inflammatory state, predisposing to cirrhosis and liver cancer, particularly hepatocellular carcinoma (HCC). A role for Toll-like receptor (TLR) signalling in hepatocarcinogenesis was recently documented. We hypothesised a link TLR3 and TLR4 polymorphisms and HCC, as surrogates for the significance of TLR signalling in the promotion and initiation of HCC.
Materials And Methods: We recruited 174 HCV-infected patients, 100 HBV-infected patients and 360 healthy control subjects. TLR3 (rs3775290) and TLR4 (rs4986790) genotyping was done by PCR-restriction fragment length polymorphisms (PCR-RFLP), LFTs and AFP by standard routine techniques. Liver fibrosis was assessed clinically by the Fibrotest and Actitest.
Result: The TLR3 rs3775290 minor T genotype was linked with increased risk of chronic HBV (P = 0.05) and HCV (P = 0.031) infection. The TLR4 rs4986790 minor G genotype was linked with significantly increased risk for HBV/HCV chronic infection (P < 0.001). Subgroups analyses indicated decreased risk of HBV-related HCC in relation to TLR3 rs3775290 CC/CT genotype (P = 0.022), with increased risk ascribed to the minor (T) allele (P = 0.04). Likewise, TLR4 rs4985790 minor (GG) genotype was positively associated with HBV-linked HCC (P < 0.001). Furthermore, a link between TLR3 TT (P < 0.001) andTLR4 GG (P = 0.04) minor genotypes was noted in relation to increased risk of HCV-related disease.
Conclusion: TLR3 and TLR4 polymorphisms are promising biomarkers of liver cirrhosis and cancer associated with HBV and HCV infection.
Awadh A, Alharthi A, Alghamdi B, Alghamdi S, Baqays M, Binrabaa I J Glob Infect Dis. 2025; 16(4):127-134.
PMID: 39886088 PMC: 11775402. DOI: 10.4103/jgid.jgid_211_23.
Soumbara T, Bonnet C, Hamed C, Veten F, Hemeyine M, Fall-Malick F BMC Infect Dis. 2024; 24(1):616.
PMID: 38907187 PMC: 11191147. DOI: 10.1186/s12879-024-09503-w.
Soleiman-Meigooni S, Yarahmadi A, Kheirkhah A, Afkhami H Front Immunol. 2024; 15:1363996.
PMID: 38545106 PMC: 10965641. DOI: 10.3389/fimmu.2024.1363996.
Du Y, Li S, Wang X, Liu J, Gao Y, Lv W Front Microbiol. 2023; 14:1330170.
PMID: 38075931 PMC: 10698469. DOI: 10.3389/fmicb.2023.1330170.
Papadakos S, Arvanitakis K, Stergiou I, Vallilas C, Sougioultzis S, Germanidis G Pharmaceutics. 2023; 15(10).
PMID: 37896221 PMC: 10610499. DOI: 10.3390/pharmaceutics15102460.